Overview

Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)

Status:
Completed
Trial end date:
2018-03-20
Target enrollment:
Participant gender:
Summary
Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in patients with resistance to Eculizumab due to complement C5 polymorphisms.
Phase:
Phase 2
Details
Lead Sponsor:
AKARI Therapeutics
Collaborator:
Radboud University
Treatments:
Complement System Proteins